Main news

 


 

Lower CVD Risk With Stable DMARD Therapy in Seropositive Rheumatoid Arthritis
Lower CVD Risk With Stable DMARD Therapy in Seropositive Rheumatoid Arthritis The risk for cardiovascular diseases (CVDs) is lower in patients with seropositive rheumatoid arthritis (RA) who remain on stable disease-modifying antirheumatic drug (DMARD) therapy than in those whose treatment regimen is not stable.


Novel PCSK9 Inhibitor Reduced LDL by 50%
Novel PCSK9 Inhibitor Reduced LDL by 50% Lerodalcibep, a novel, third-generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, reduced low-density lipoprotein cholesterol (LDL-C) by more than 50% after 1 year in patients with or at a high risk for cardiovascular disease (CVD), new phase 3 results showed.


Editorial Activity

cardiology book

Trial Evaluating Sacubitril/Valsartan for HFpEF Misses Primary End Point
Trial Evaluating Sacubitril/Valsartan for HFpEF Misses Primary End Point Full detailed data from PARAGON-HF will be presented at the ESC Congress 2019 in September. Novartis announced topline results from the phase 3 PARAGON-HF study evaluating the safety and efficacy of sacubitril/valsartan (Entresto) in heart failure patients with preserved ejection fraction (HFpEF).


ESC Congress 2019                      together with World Congress of Cardiology
ESC Congress 2019 together with World Congress of Cardiology Full detailed data from PARAGON-HF will be presented at the ESC Congress 2019 in September. Novartis announced topline results from the phase 3 PARAGON-HF study evaluating the safety and efficacy of sacubitril/valsartan (Entresto) in heart failure patients with preserved ejection fraction (HFpEF).


Certain Social, Behavioral Factors Associated With Diabetes and Hypertension Onset
Certain Social, Behavioral Factors Associated With Diabetes and Hypertension Onset Education and exercise may determine early start of diabetes and hypertension. Select behavioral and social risk factors were correlated with early onset of hypertension and diabetes, a prospective cohort study found. At 3.5 years of follow-up, among the patients without diabetes at baseline, 4% developed diabetes, while 6.4% of the cohort without baseline hypertension developed hypertension, reported Matthew Pantell, MD, MS, of the University of California, San Francisco, and colleagues.


THE FEATS OF DOCTORS DURING  THE GREAT PATRIOTIC WAR (WORLD WAR II)
THE FEATS OF DOCTORS DURING THE GREAT PATRIOTIC WAR (WORLD WAR II) During the war years, more than 700 thousand doctors and medical professionals worked at the front. At the end of the war, 12.5% of all these people were killed, and this figure seriously exceeds the losses in each individual military unit. But despite the danger, they never gave up, and in the most extreme situations only the iron will helped them to pull hundreds of people from the other world, and again to return to the battlefields. They achieved amazing results, and during the entire war, thanks to medical workers, about 72 percent of wounded soldiers and 90 percent of sick people, that is, approximately 17 million people, returned to the system.


The Congress for Cardiology and Internal medicine of Asian and CIS countries
The Congress for Cardiology and Internal medicine of Asian and CIS countries On April 26 - 27, 2019, the Congress for Cardiology and Internal medicine of Asian and CIS countries was held in Dushanbe (Tajikistan). The congress was organized by the Ministry of Health and Social Protection of Tajikistan and the Cardioprogress Foundation. In the opening ceremony, the Minister, Professor Olimzoda Nasim Khoja addressed the participants with greetings.


Stress-Related Disorders Increase CVD Risk
Stress-Related Disorders Increase CVD Risk Stress-related disorders may increase the risk for cardiovascular disease (CVD), especially during the first year after diagnosis, a large study shows.



FDA's Assessment of Currently Marketed ARB drug products
FDA's Assessment of Currently Marketed ARB drug products FDA has worked with manufacturers to swiftly remove angiotensin II receptor blocker (ARB) drug products with impurity levels above interim acceptable limits. Those products have been removed from the market and have been posted in our recall lists for ARB products.